GTBP News and Press, GT Biopharma Inc.

A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs PR Newswire Issued on behalf of GT Biopharma, Inc. GT Biopharma, Inc. (NASDAQ: GTBP) said it has integrated AI-based tools across the discovery and engine...

A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs PR Newswire Issued on behalf of GT Biopharma, Inc. GT Biopharma, Inc. (NASDAQ: GTBP) says newly implemented AI-based tools are accelerating its drug discovery and enginee...

Issued on behalf of GT Biopharma, Inc. Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else. SAN FRANCISCO, June 12...

Issued on behalf of GT Biopharma, Inc. (Nasdaq: GTBP) A clinical-stage immuno-oncology company has moved three drug candidates into human testing over time --- and most recently expanded into solid tumors --- while carrying a market value that remains modest relative to many clinical-stage on...

Increased integration of artificial intelligence–based tools across the discovery and engineering of tumor-targeting engagers and multi-domain proteins to accelerate development while reducing developmental costs Reduces reliance on trial-and-error experimentation, shortens development...

The $13 Million Company Teaching the Immune System to Hunt Cancer Canada NewsWire Issued on behalf of GT Biopharma, Inc. (NASDAQ: GTBP) Three drugs in human trials. A platform licensed from one of the world ' s top cancer-research universities. A market cap smaller than a Manh...

Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes PR Newswire Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. Companies mentioned: GT Biopharma, Inc. (NASDAQ: GTBP), Fate Therapeutics, Inc. (NASDAQ: FATE), Nkarta, Inc. (NASDAQ: NKT...

B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic Canada NewsWire Issued on behalf of GT Biopharma, Inc.   SAN FRANCISCO , May 18, 2026 /CNW/ -- USA News Group News Commentary — For more than two decades, B7-H3 sat on the shortlist of...

2026-05-15 08:38:39 ET More on GT Biopharma GT Biopharma reports FY results Seeking Alpha’s Quant Rating on GT Biopharma Historical earnings data for GT Biopharma Financial information for GT Biopharma Read the full article on Seeking Alpha ...

Phase 1 trial evaluating GTB-3650 TriKE ® remains ongoing, with additional updates anticipated in 2H 2026 Phase 1 basket trial evaluating GTB-5550 TriKE ® in multiple solid tumor types known to express B7-H3 initiated May 2026 with updates anticipated in 2H 2026 as enr...